JonesResearch initiated coverage of CG Oncology (CGON) with a Buy rating and $50 price target The late-stage company is developing an oncolytic virus, cretostimogene grenadenorepvec, in multiple settings of Non-Muscle Invasive Bladder Cancer, notes the analyst, who calls CG “a good bet in the bladder cancer space” with a strong cash position to fund several of trials through regulatory filings and “a fairly derisked drug with potentially best-in-class efficacy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Buy Rating for CG Oncology: Promising NMIBC Treatment and Strong Financial Position
- Buy Rating for CG Oncology, Inc.: Promising Data on Creto’s Efficacy and Safety in NMIBC Treatment
- CG Oncology’s Promising Clinical Results and Strategic Positioning Drive Buy Rating
- Promising Phase 3 Results for CG Oncology’s Cretostimogene Highlight Competitive Edge in Bladder Cancer Treatment
- Promising Outlook for CG Oncology, Inc.: Buy Rating Supported by Cretostimogene’s Efficacy and Market Potential